NASDAQ · ACIU
AC Immune SA financials
$2.60−0.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M | $30.2M | $17.6M | $4.3M | $0.00 | $17.2M | $110.5M | $6.9M | $20.3M | $23.2M |
| Gross profit | $4.5M | $30.2M | $17.6M | $4.3M | $0.00 | $17.2M | $110.5M | $6.9M | $20.3M | $23.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$87.4M | -$58.0M | -$63.8M | -$76.6M | -$79.0M | -$68.2M | $44.5M | -$49.5M | -$22.5M | -$10.5M |
| Net income | -$88.8M | -$56.4M | -$64.5M | -$76.5M | -$73.0M | -$68.9M | $45.4M | -$51.0M | -$26.4M | -$7.1M |
| Net margin | −1971.6% | −186.4% | −366.4% | −1798.0% | — | −401.3% | 41.1% | −737.1% | −130.4% | −30.6% |
| Diluted EPS | $-0.88 | $-0.56 | $-0.76 | $-0.92 | $-0.97 | $-0.96 | $0.64 | $-0.82 | $-0.46 | $-0.14 |
| EBITDA | -$85.0M | -$56.3M | -$61.8M | -$74.7M | -$77.1M | -$66.5M | $45.8M | -$48.6M | -$22.0M | -$10.2M |
| Operating cash flow | -$87.3M | $72.9M | -$71.8M | -$79.6M | -$65.7M | -$66.3M | $55.2M | -$44.1M | -$22.1M | -$5.6M |
| Free cash flow | -$88.4M | $72.3M | -$72.8M | -$80.9M | -$68.3M | -$68.2M | $53.3M | -$45.9M | -$23.9M | -$6.5M |
| Diluted shares | 100.8M | 99.7M | 84.7M | 83.6M | 75.0M | 71.9M | 71.1M | 61.8M | 57.1M | 50.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.8M | $40.2M | $93.3M | $31.6M | $90.2M | $160.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $65.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $194.4M | $255.6M | $217.4M | $185.9M | $286.8M | $238.7M |
| Total liabilities | $137.8M | $131.3M | $26.4M | $16.9M | $32.3M | $23.3M |
| Shareholders' equity | $56.6M | $124.3M | $191.0M | $169.0M | $254.4M | $215.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology